106 related articles for article (PubMed ID: 37394589)
1. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer.
Kim JY; Park S; Cho EY; Lee JE; Jung HH; Chae BJ; Kim SW; Nam SJ; Cho SY; Park YH; Ahn JS; Lee S; Im YH
Exp Mol Med; 2023 Jul; 55(7):1451-1461. PubMed ID: 37394589
[TBL] [Abstract][Full Text] [Related]
2. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
[TBL] [Abstract][Full Text] [Related]
3. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.
Cobleigh MA; Layng KV; Mauer E; Mahon B; Hockenberry AJ; Abukhdeir AM
Breast Cancer Res Treat; 2024 Apr; 204(2):407-414. PubMed ID: 38153569
[TBL] [Abstract][Full Text] [Related]
5. Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Prat A; Lluch A; Albanell J; Barry WT; Fan C; Chacón JI; Parker JS; Calvo L; Plazaola A; Arcusa A; Seguí-Palmer MA; Burgues O; Ribelles N; Rodriguez-Lescure A; Guerrero A; Ruiz-Borrego M; Munarriz B; López JA; Adamo B; Cheang MC; Li Y; Hu Z; Gulley ML; Vidal MJ; Pitcher BN; Liu MC; Citron ML; Ellis MJ; Mardis E; Vickery T; Hudis CA; Winer EP; Carey LA; Caballero R; Carrasco E; Martín M; Perou CM; Alba E
Br J Cancer; 2014 Oct; 111(8):1532-41. PubMed ID: 25101563
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic.
Rojas-Jiménez E; Mejía-Gómez JC; Díaz-Velásquez C; Quezada-Urban R; Martínez Gregorio H; Vallejo-Lecuona F; de la Cruz-Montoya A; Porras Reyes FI; Pérez-Sánchez VM; Maldonado-Martínez HA; Robles-Estrada M; Bargalló-Rocha E; Cabrera-Galeana P; Ramos-Ramírez M; Chirino YI; Alonso Herrera L; Terrazas LI; Oliver J; Frecha C; Perdomo S; Vaca-Paniagua F
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227964
[TBL] [Abstract][Full Text] [Related]
7. Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
Abadie J; Nguyen F; Loussouarn D; Peña L; Gama A; Rieder N; Belousov A; Bemelmans I; Jaillardon L; Ibisch C; Campone M
Breast Cancer Res Treat; 2018 Jan; 167(2):459-468. PubMed ID: 29063312
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling in triple-negative breast cancer.
Liedtke C; Bernemann C; Kiesel L; Rody A
Breast Care (Basel); 2013 Dec; 8(6):408-13. PubMed ID: 24550748
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
10. Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer.
Cabioglu N; Bayram A; Emiroglu S; Onder S; Karatay H; Oner G; Tukenmez M; Muslumanoglu M; Igci A; Aydiner A; Saip P; Yavuz E; Ozmen V
Front Oncol; 2023; 13():1165257. PubMed ID: 37519808
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy: A Promising New Standard of Care.
Boydell E; Sandoval JL; Michielin O; Obeid M; Addeo A; Friedlaender A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511609
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.
Srivastava N; Usmani SS; Subbarayan R; Saini R; Pandey PK
Front Oncol; 2023; 13():1199105. PubMed ID: 37492478
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract][Full Text] [Related]
14. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
15. Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline
Nerone M; Rossi L; Condorelli R; Ratti V; Conforti F; Palazzo A; Graffeo R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444415
[TBL] [Abstract][Full Text] [Related]
16. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F; Dewanjee S; Li Y; Jha NK; Chen ZS; Kumar A; Vishakha ; Behl T; Jha SK; Tang H
Mol Cancer; 2023 Jul; 22(1):105. PubMed ID: 37415164
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer.
Choi H; Ahn SG; Bae SJ; Kim JH; Eun NL; Lee Y; Nahm JH; Jeong J; Cha YJ
Yonsei Med J; 2023 Aug; 64(8):518-525. PubMed ID: 37488704
[TBL] [Abstract][Full Text] [Related]
18. Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
Jinna ND; Van Alsten S; Rida P; Seewaldt VL; Troester MA
Breast Cancer Res Treat; 2023 Sep; 201(2):171-181. PubMed ID: 37438515
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
[TBL] [Abstract][Full Text] [Related]
20. QSOX2 Upregulated in triple-negative breast cancer exacerbates patient prognosis by stabilizing integrin β1.
Kim AI; Oh JH; Cho JY
Heliyon; 2024 Mar; 10(6):e27148. PubMed ID: 38500982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
